SION

Sionna Therapeutics, Inc. Common Stock

SION

Market cap $1.01B

Overview Fund Activity

22.83 USD

-0.97

4.08%

At close Updated Sep 12, 4:00 PM EDT

1 day

-4.08%

5 days

-8.64%

1 month

8.77%

3 months

34.37%

6 months

33.43%

Year to date

-8.68%

1 year

-8.68%

5 years

-8.68%

10 years

-8.68%

About: Sionna Therapeutics Inc is a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (CF) patients by developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (CFTR) protein to deliver clinically meaningful benefit to CF patients. CF is a progressive and life-threatening genetic disease caused by inherited mutations in the CFTR gene, which heads to insufficient CFTR function. The Company is managed as one operating segment focused on the research and development of cystic fibrosis therapies.

Employees: 48

Healthcare Biotechnology

0

Funds holding %

of 7,462 funds

0

Analysts bullish %

of 3 analysts

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

225% more first-time investments, than exits

New positions opened: 26 | Existing positions closed: 8

100% more funds holding in top 10

Funds holding in top 10: 2 [Q1] → 4 (+2) [Q2]

80% more repeat investments, than reductions

Existing positions increased: 18 | Existing positions reduced: 10

74% more capital invested

Capital invested by funds: $434M [Q1] → $754M (+$320M) [Q2]

38% more funds holding

Funds holding: 47 [Q1] → 65 (+18) [Q2]

4.42% more ownership

Funds ownership: 94.04% [Q1] → 98.47% (+4.42%) [Q2]

See Fund Rankings

Research analyst outlook

3 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$22

-4% downside

Avg. target

$38

65% upside

High target

$46

101% upside

3 analyst ratings

2 positive

67%

1 neutral

33%

0 negative

0%

Jones Trading Debanjana Chatterjee	$46	Buy Initiated	8 Sep 2025
Raymond James Chris Raymond	$45	Strong Buy Initiated	3 Sep 2025
RBC Capital Brian Abrahams	$22	Sector Perform Initiated	3 Sep 2025

See Analyst Rankings

Financial journalist opinion

Based on 6 articles about SION published over the past 30 days

Stock Picks From Seeking Alpha's August 2025 New Analysts

In August, Seeking Alpha welcomed 26 new analysts. This article introduces them and showcases some of their top picks. Analysts highlighted include The J Thesis, recommending PayPal; Ihor Pohkyton, on Keurig Dr Pepper; and David Hotea, writing about Cleveland-Cliffs—all rated as Buys. Analysts' diverse backgrounds span sectors like financials, semiconductors, and utilities, with investment strategies focusing on value and growth investing and options trading.

Stock Picks From Seeking Alpha's August 2025 New Analysts

Zacks Investment Research

Wall Street Analysts See a 66.51% Upside in Sionna Therapeutics, Inc. (SION): Can the Stock Really Move This High?

The mean of analysts' price targets for Sionna Therapeutics, Inc. (SION) points to a 66.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Wall Street Analysts See a 66.51% Upside in Sionna Therapeutics, Inc. (SION): Can the Stock Really Move This High?

Sionna Therapeutics, Inc. (SION) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)

Sionna Therapeutics, Inc. (NASDAQ:SION ) Morgan Stanley 23rd Annual Global Healthcare Conference September 8, 2025 7:00 AM EDT Company Participants Michael Cloonan - President, CEO & Director Charlotte McKee - Chief Medical Officer Elena Ridloff - CFO & Head of Corporate Development Presentation Unknown Analyst Well, welcome, guys. Before we start, I'm just going to read a brief disclaimer.

Sionna Therapeutics, Inc. (SION) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)

Sionna Therapeutics Appoints Caroline Stark Beer as Chief Business Officer

WALTHAM, Mass., Sept. 08, 2025 (GLOBE NEWSWIRE) -- Sionna Therapeutics, Inc. (Nasdaq: SION), a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (CF) by developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (CFTR) protein, today announced the appointment of Caroline Stark Beer, MBA, as its Chief Business Officer (CBO).

Sionna Therapeutics Appoints Caroline Stark Beer as Chief Business Officer

Sionna Therapeutics to Participate in Upcoming September Investor Conferences

WALTHAM, Mass., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Sionna Therapeutics, Inc. (Nasdaq: SION), a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (CF) by developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (CFTR) protein, today announced that management will participate in fireside chats at the following upcoming investor events:

Sionna Therapeutics to Participate in Upcoming September Investor Conferences

Sionna Therapeutics Announces First Subjects Dosed in Phase 1 Trial Evaluating NBD1 Stabilizer, SION-451, in Proprietary Dual Combinations in Development for the Treatment of Cystic Fibrosis

Dosing initiated for SION-451 combined with SION-2222 and SION-451 combined with SION-109 in healthy volunteers; topline data anticipated in mid-2026 Dosing initiated for SION-451 combined with SION-2222 and SION-451 combined with SION-109 in healthy volunteers; topline data anticipated in mid-2026

Sionna Therapeutics Announces First Subjects Dosed in Phase 1 Trial Evaluating NBD1 Stabilizer, SION-451, in Proprietary Dual Combinations in Development for the Treatment of Cystic Fibrosis

Sionna Therapeutics Reports Second Quarter 2025 Financial Results

Announced positive Phase 1 data for SION-719 and SION-451 demonstrating both first-in-class NBD1 stabilizers were generally well tolerated and exceeded pharmacokinetic targets Initiation of Phase 2a proof-of-concept trial of SION-719 as an add-on to standard of care in cystic fibrosis patients is on track for the second half of 2025 with topline data expected in mid-2026 Advancement of Phase 1 healthy volunteer trial of SION-451 in two proprietary dual combinations is on track for the second half of 2025 with topline data expected in mid-2026 Maintained strong cash position with approximately $337.3 million in cash and cash equivalents, expected to fund operations into 2028 WALTHAM, Mass., Aug. 11, 2025 (GLOBE NEWSWIRE) -- Sionna Therapeutics, Inc. (Nasdaq: SION), a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (CF) by developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (CFTR) protein, today reported financial results for the quarter ended June 30, 2025, and provided a business update.

Sionna Therapeutics Reports Second Quarter 2025 Financial Results

Sionna Therapeutics Announces Presentation of Preclinical Data that Demonstrate Proprietary Dual Combination Therapies Enable Full CFTR Correction in CFHBE Model

Data featured in oral presentation and poster session at 48 th European Cystic Fibrosis Conference

Sionna Therapeutics Announces Presentation of Preclinical Data that Demonstrate Proprietary Dual Combination Therapies Enable Full CFTR Correction in CFHBE Model

Sionna Therapeutics Announces Positive Phase 1 Data for NBD1 Stabilizers SION-719 and SION-451 and Advances Both Programs in Clinical Development for Cystic Fibrosis

SION-719 and SION-451 were generally well tolerated and achieved desired pharmacokinetic targets that reinforce their potential as either an add-on to standard of care or in a Sionna dual combination Sionna plans to advance SION-719 to a Phase 2a proof-of-concept add-on to standard of care trial in cystic fibrosis patients, and SION-451 to a Phase 1 healthy volunteer dual combination trial Next trials to initiate in the second half of 2025 with topline data expected in mid-2026 Sionna to hold a conference call today at 8:00 a.m. ET WALTHAM, Mass.

Sionna Therapeutics Announces Positive Phase 1 Data for NBD1 Stabilizers SION-719 and SION-451 and Advances Both Programs in Clinical Development for Cystic Fibrosis

Sionna Therapeutics to Present at the Goldman Sachs 46th Annual Global Healthcare Conference

WALTHAM, Mass., June 03, 2025 (GLOBE NEWSWIRE) -- Sionna Therapeutics, Inc. (Nasdaq: SION), a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (CF) by developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (CFTR) protein, today announced that management will participate in a fireside chat at the Goldman Sachs 46th Annual Healthcare Conference in Miami, Florida on Wednesday, June 11th 2025 at 8:00 a.m.

Sionna Therapeutics to Present at the Goldman Sachs 46th Annual Global Healthcare Conference

See News Rankings

Charts implemented using Lightweight Charts™